We serve 1-phenyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzimidazole CAS:952514-86-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![1-phenyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzimidazole](https://a.dearchem.com/uploads/userup/0/15H240934-1164.png)
Contact us for information like 1-phenyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Phenyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-benzo[d]imidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1-phenyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]benzimidazole Use and application,3-(1-phenyl-1h-benzimidazole-2-yl)phenylboronic acid pinacol ester technical grade,usp/ep/jp grade.
Related News: What’s the background?Cysteamine hydrochloride manufacturer What’s the background?dimethyl 2-(4-methoxycarbonyl-2-nitrophenyl)propanedioate supplier Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).4-Pentylbenzeneboronic acid vendor Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with an initial focus on Myelodysplastic Syndromes (MDS).
